We had a quiet Sunday as I did a little in the garden
Today we had the thrill of getting the Motorhome to the Garage for its MOT.
We took Louis with the intention of a lovely country walk in the park.
It was very sunny but the wind is bitter cold. Walking into the wind we froze and then turn back with the wind on our backs and the sun on our face it was warm.
Having walked the dog sufficiently Ray and I turned back and went into the waiting room as the M/H was being worked on still. You sit there like a doctors waiting room, waiting to see if the news is good or bad, but our little love didnt let us down and passed with flying colours. Bless her she is already for a good trip out.
Home now and settled with a coffee and our nerves are back in place.
We all have our fingers crossed for two Warriors. James who is in chemo and waiting to go on the Command Trial, and Steve who is waiting to see if the results of his scan are good or bad, Steve may or may not continue treatment with vandetanib and selumetinib. However, he’s done his bit for medical research for the time being, so no more “PK” bloods over a 24 hour period – just going back to hospital for monthly check ups if the drugs have worked for him and he decides to continue.
I wasnt dreaming then we had crime come to our door step Saturday night
This becomes very frightening as we never know when these things happen and in a very quiet spot.
Police helicopter helped to track down a 19-year-old from Whitstable after two men were assaulted
Two men were taken to hospital with knife injuries last night after they were assaulted in Whitstable.
A 19-year-old Whitstable man was located by a police helicopter and arrested on suspicion of assault.
The two injured men, also aged 19, had been assaulted in Church Lane, Seasalter, at around 11.10pm.
They were taken to hospital to be treated for knife injuries, described as not serious.
It is understood that the men are all known to each other and the man arrested remains in custody.
Professor David Walker explains why the Saatchi Bill will lead to new therapies for thousands of desperate patients
Based at Nottingham University for the past 22 years, working at Nottingham Children’s Hospital and Nottingham Medical School, Prof Walker combines a passionate commitment to the welfare of his patients with a deep respect for scientific discipline.
He wants to see more and better therapies added to the armoury of paediatric cancer treatments, to save the lives of more children, and is frustrated by the obstacles that block the path to new cures for cancers.
Medical science decrees that no new treatment should be used until it has been thoroughly tested in randomised clinical trials. Trials are the gold standard, Prof Walker stresses, and where possible patients should be in a trial if one is available. “Research does require regulation to introduce new drugs and treatment safely,” he says.
But trials alone cannot meet the desperate need for new treatments, in particular for rare cancers. “There will never be enough trials, they take years, and in any event there are rarely trials for less common diseases. There just aren’t enough patients.
Around one in 600 children under 16 are diagnosed with cancers. The most common, such as leukaemia, account for a third of cases, and treatment success rates are high. But some are hard to treat, other than with surgery, such as the highly malignant rhabdoid tumours, which start in the kidney. There are no standard therapies for these cancers and less than one in five children diagnosed with a stage III or IV rhabdoid tumour will survive beyond four years.
With such rare childhood cancers, it is hard to gather enough patients to form a trial in one country alone, and these have to be organised internationally.
“The problem is that there are many different tumour types and sub-types in childhood cancers, each having an unique biological signature justifying a unique scientific rationale for their treatment with modern drugs in development,” says Prof Walker. “They are all rare in the population and there is a huge element of luck as to whether in your child’s case there is a trial available.”
So, while potential new drugs may exist, they cannot be used. “A drug may be available, the scientific rationale for its use may exist, but patients cannot receive it if no trial has been organised to assess its effectiveness and toxicity,” says Prof Walker.
He also points out that the “big four” cancers – breast, bowel, lung and prostate – dominate media coverage as well as fundraising, research and trials. Researchers want to work on the common cancers because their research will be better funded, while drugs companies are more interested in this area as there is a bigger market, and a greater potential profit.
If you have a less common cancer – and there are hundreds – your chances of getting on a trial are limited and the chances of there being innovative treatments are, in many cases, zero. Yet taken together, less common cancers – defined as a cancer that affects five people or fewer in 10,000 – account for more than half of all British cancer deaths. One in six of us will develop and die from a rare cancer.
The lack of trials in this area means doctors who want to cure their patients, rather than just manage their deaths, are caught in a scientific circular argument. There is no evidence that a new treatment will work, so it cannot be used to find out if it does work.
Prof Walker believes that doctors should be able to try new treatments with such patients on an individual basis. Yet, he argues, the law, and the culture of defensive medicine which surrounds it, stands in the way of innovation. Doctors are protected if they stick to the well-worn path of “standard procedure” even if it leads to the death of the patient. But they may be vulnerable to legal action if they try something new and it fails.
Which is why Prof Walker supports Maurice Saatchi’s Medical Innovation Bill, currently going through a public consultation process by the Department of Health, which ends later this month. It seeks to provide legal protection for doctors who innovate in the interests of their patients. He argues that when patients are terminally ill and there is no trial for which they are eligible, a doctor should be free to innovate.
“We need to allow them to try new drugs outside of a formal trial and collect the data from those innovations to inform the next generation of trials,” he says. “The Saatchi Bill would protect individual doctors who try new, untrialled treatments, where there is a scientific rationale for their use, in patients who consent.
“This isn’t a licence for the maverick doctor acting alone – the Bill obliges the doctor to seek agreement from peers.”
The Saatchi Bill, he believes “will give the patients and their families additional choice and allow doctors to try new medicines in people who have nowhere else to go, and do it in such a way as we could all learn from it”.
Prof Walker also believes that even when an individual patient cannot be cured, this kind of innovation will advance medical science for future patients.
“When people are dying,” he says, “they all would like their passage through their illness to have some meaning and to learn from the loss of their life.”
He also explains that many cancer drug trials rightly focus hard on a tightly defined group of patients with the same tumour type, which has within it a particular cancer molecule, that the drug being tested is designed to block.
Using molecularly targeted drugs in patients with the same tumour drives robust results. But, says Prof Walker, “there is a weakness in the process, because it doesn’t tell you where else the new drug may work. It only tells you that the drug works on a very specific patient type with a very specific tumour which has within it that particular molecular target.”
The new drug may work in another rarer cancer with the same molecular target, he says. “But if I have a patient with a very rare cancer with the same molecular target, I can’t use it. Current rules require us to set up another trial in that tumour, and that’s expensive and requires collaboration with the drug industry, which may not wish to supply the drug for such a purpose if they don’t think it is commercially advantageous. So, in the meantime, the hospital won’t release that licensed drug for an unlicensed purpose because there’s no evidence that it works,” he says.
This is where the Lord Saatchi’s Medical Innovation Bill would help, he argues.
“If we could test drugs in a patient and record our results in an open-access database, this would contribute to our understanding of the application of this drug and perhaps help with selecting new drugs for clinical trial by identifying those with most promise; although it is important that the drug has already been tested fully on patients with a different cancer but with the same molecular signature.”
Opponents of the Bill argue that a law that supports doctors who want to try new treatments outside the trial process is a “quack’s charter”.
Prof Walker disagrees: “To offer an untried treatment and not learn from the process would be quackery.” “But to use untried treatment and to try to learn, responsibly, about the effect on the individual, and share that learning with others would seem to be not quackery, but actually responsible professional practice.”
To urge the Government to enact the Medical Innovation Bill, sign the petition at http://chn.ge/1pqY6lS. For more information, see saatchibill.tumblr.com or tinyurl.com/saatchibill. Follow@SaatchiBill on Twitter